Logo image of XERS

XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Fundamental Analysis

NASDAQ:XERS - US98422E1038 - Common Stock

7.82 USD
+0.07 (+0.9%)
Last: 8/25/2025, 11:32:03 AM
Fundamental Rating

3

XERS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of XERS have multiple concerns. XERS is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year XERS has reported negative net income.
XERS had a negative operating cash flow in the past year.
XERS had negative earnings in each of the past 5 years.
In the past 5 years XERS always reported negative operating cash flow.
XERS Yearly Net Income VS EBIT VS OCF VS FCFXERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -14.29%, XERS is in the better half of the industry, outperforming 63.73% of the companies in the same industry.
Industry RankSector Rank
ROA -14.29%
ROE N/A
ROIC N/A
ROA(3y)-21.25%
ROA(5y)-32.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XERS Yearly ROA, ROE, ROICXERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Gross Margin of XERS (82.21%) is better than 87.05% of its industry peers.
In the last couple of years the Gross Margin of XERS has grown nicely.
XERS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.81%
GM growth 5Y14.98%
XERS Yearly Profit, Operating, Gross MarginsXERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

XERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
XERS has more shares outstanding than it did 1 year ago.
XERS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, XERS has a worse debt to assets ratio.
XERS Yearly Shares OutstandingXERS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
XERS Yearly Total Debt VS Total AssetsXERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

XERS has an Altman-Z score of -0.15. This is a bad value and indicates that XERS is not financially healthy and even has some risk of bankruptcy.
XERS's Altman-Z score of -0.15 is in line compared to the rest of the industry. XERS outperforms 51.30% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.15
ROIC/WACCN/A
WACC10.6%
XERS Yearly LT Debt VS Equity VS FCFXERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 1.72 indicates that XERS should not have too much problems paying its short term obligations.
XERS's Current ratio of 1.72 is on the low side compared to the rest of the industry. XERS is outperformed by 63.73% of its industry peers.
A Quick Ratio of 1.17 indicates that XERS should not have too much problems paying its short term obligations.
XERS has a worse Quick ratio (1.17) than 69.95% of its industry peers.
Industry RankSector Rank
Current Ratio 1.72
Quick Ratio 1.17
XERS Yearly Current Assets VS Current LiabilitesXERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 51.16% over the past year.
The Revenue has grown by 23.89% in the past year. This is a very strong growth!
Measured over the past years, XERS shows a very strong growth in Revenue. The Revenue has been growing by 137.28% on average per year.
EPS 1Y (TTM)51.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90%
Revenue 1Y (TTM)23.89%
Revenue growth 3Y59.98%
Revenue growth 5Y137.28%
Sales Q2Q%48.84%

3.2 Future

XERS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.91% yearly.
The Revenue is expected to grow by 21.10% on average over the next years. This is a very strong growth
EPS Next Y82.1%
EPS Next 2Y61.12%
EPS Next 3Y45.4%
EPS Next 5Y34.91%
Revenue Next Year42.48%
Revenue Next 2Y30.98%
Revenue Next 3Y25.91%
Revenue Next 5Y21.1%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
XERS Yearly Revenue VS EstimatesXERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
XERS Yearly EPS VS EstimatesXERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XERS. In the last year negative earnings were reported.
XERS is valuated quite expensively with a Price/Forward Earnings ratio of 34.53.
XERS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. XERS is cheaper than 69.43% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of XERS to the average of the S&P500 Index (22.81), we can say XERS is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 34.53
XERS Price Earnings VS Forward Price EarningsXERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XERS Per share dataXERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
XERS's earnings are expected to grow with 45.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y61.12%
EPS Next 3Y45.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XERS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XERIS BIOPHARMA HOLDINGS INC

NASDAQ:XERS (8/25/2025, 11:32:03 AM)

7.82

+0.07 (+0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners54.31%
Inst Owner Change3.2%
Ins Owners2.93%
Ins Owner Change1.1%
Market Cap1.26B
Analysts85
Price Target9.18 (17.39%)
Short Float %11.88%
Short Ratio7.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.63%
Min EPS beat(2)-10.3%
Max EPS beat(2)53.56%
EPS beat(4)2
Avg EPS beat(4)7.88%
Min EPS beat(4)-19.83%
Max EPS beat(4)53.56%
EPS beat(8)3
Avg EPS beat(8)3.77%
EPS beat(12)7
Avg EPS beat(12)10.13%
EPS beat(16)8
Avg EPS beat(16)1.19%
Revenue beat(2)2
Avg Revenue beat(2)1.86%
Min Revenue beat(2)1.41%
Max Revenue beat(2)2.31%
Revenue beat(4)4
Avg Revenue beat(4)2.51%
Min Revenue beat(4)1.41%
Max Revenue beat(4)3.44%
Revenue beat(8)6
Avg Revenue beat(8)3.44%
Revenue beat(12)9
Avg Revenue beat(12)2.94%
Revenue beat(16)10
Avg Revenue beat(16)1.75%
PT rev (1m)36.71%
PT rev (3m)44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)17.49%
EPS NY rev (1m)24.24%
EPS NY rev (3m)-33.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.32%
Revenue NY rev (1m)6.34%
Revenue NY rev (3m)7.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 34.53
P/S 5.67
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)0.23
Fwd EY2.9%
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS1.38
BVpS-0.22
TBVpS-0.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.21%
FCFM N/A
ROA(3y)-21.25%
ROA(5y)-32.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.81%
GM growth 5Y14.98%
F-Score4
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.63%
Cap/Sales 0.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.72
Quick Ratio 1.17
Altman-Z -0.15
F-Score4
WACC10.6%
ROIC/WACCN/A
Cap/Depr(3y)9.44%
Cap/Depr(5y)22.43%
Cap/Sales(3y)0.76%
Cap/Sales(5y)1.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90%
EPS Next Y82.1%
EPS Next 2Y61.12%
EPS Next 3Y45.4%
EPS Next 5Y34.91%
Revenue 1Y (TTM)23.89%
Revenue growth 3Y59.98%
Revenue growth 5Y137.28%
Sales Q2Q%48.84%
Revenue Next Year42.48%
Revenue Next 2Y30.98%
Revenue Next 3Y25.91%
Revenue Next 5Y21.1%
EBIT growth 1Y49.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year188.98%
EBIT Next 3Y72.81%
EBIT Next 5Y46.27%
FCF growth 1Y66.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.87%
OCF growth 3YN/A
OCF growth 5YN/A